Take Solutions, an international business technology firm, today said it has entered into an agreement with South Korea-based IL-Yang Pharma Company Ltd for providing investigational new drug (IND) submission services to the company.
The purpose of the IND submission is to gain Food and Drug Administration (FDA) non-objection to study the investigational agent in humans, Take Solutions said in a filing to the Bombay Stock Exchange.
"Our reworked strategy toward focusing on the Asia Pacific region has received a major boost with IL-Yang Pharma," Take Solutions Vice President — sales, Life Sciences APAC, L Ramesh said.
The IND submission must include, sufficient preclinical data, details of chemistry and description of mechanism of action of the agent, the filing added.
Shares of Take Solutions were trading at Rs 38.30, up 8.50 per cent on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app